Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted AML1-ETO Neoantigen CTL in Relapsed/Refractory t(8;21) AML
NCT06499025Phase 1Enrolling by invitation
- Sponsor
- BGI
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of targeted AML1-ETO neoantigen cytotoxic T cells in acute myeloid leukemia (AML), sponsored by BGI. Primary endpoint: Safety assessment (Evaluation of treatment-related adverse events according to CTCAEv5.0) at 1 year. Started Feb 2024; status: enrolling by invitation.
02
Drugs
targeted AML1-ETO neoantigen cytotoxic T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06499025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499025.